Our Value Advantage Our Value Advantage
 
Allegro in the News
Biocon to focus on Biopharmaceuticals, divesting enzymes for USD 115 million to novozymes, 18th July 2007
  Biocon announced today a definitive agreement to divest its Enzymes business vertical to Novozymes A/S for USD 115 million. This will enable Biocon to strategically focus on its core bio- pharmaceuticals business. Read more
Batting for India: Indian companies are going global. A look at three acquisitive companies that epitomise the trend - Finance Asia, May '06
  By the end of this decade we could see the deal value of India's cross-border M&A hit $25 billion annually - Kunal Kashyap, Allegro Capital Advisors. Read more
India: Bumpy road to a future of prosperity
  As familiar as the Ambassador's bulbous curves may be, India's best-known saloon car lumbers far behind rivals. Of the country's 1.3m annual car sales, only 15,000 are Ambassadors, sold mostly to government officials and taxi services. Read more
India beats UK at Capital game - Sunday Telegraph
  INDIAN investment into the UK is poised to outstrip British investment in the subcontinent, reversing the flow of capital for the first time. Read more
MANAGED ACCOUNT SERVICES
 
 
 
Contact Us Terms of Use Security & Privacy Policy
© Copyright Allegro Advisors Private Limited. All right reserved. Design & Developed by Iniquus